Genetic Therapy, Inc.

Gaithersburg, MD 20878

SBIR Award Summary

Total Number of Awards 7
Total Value of Awards $0.0
First Award Date 09/30/89
Most Recent Award Date 07/05/95

Key Personnel

Last Name Name Awards Contact
Moen Robert C Moen 1
Tolstoshev Paul Tolstoshev 1
Chiang Yawen L. Chiang 3
Mc Clelland Alan Mc 1
Chang Yung-Nien Chang 1

7 Awards Won

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 07/05/95 - 01/04/96

The objective of the proposed research is to test the capacity to increase tumor cell killing by introducing the herpes simplex virus (HSV) thymidine kinase (TK) gene on a retroviral vector and treating with ganciclovir (GCV). Our approach is to construct a retroviral vector that can be upregulated to express ...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 02/01/95 - 07/31/95

The objective of the proposed research is to test the concept of engineering the fiber protein of adenovirus to target adenovirus gene delivery vectors via cell type specific receptors. Our approach is to modify the adenovirus fiber protein by replacing the fiber head domain with ligands which bind to known cellular receptors which may be ...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 04/21/94 - 03/31/95

Adoptive immunotherapy has proven useful to treat human melanoma. The use of lymphokine activated killer cells and tumor infiltrating lymphocytes in conjunction with IL-2 have produced significant results in some terminal cancer patients. Recently, interferon alpha has been shown to have a synergistic effect with IL-2/TIL in animal TIL models....

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 04/01/93 - 03/31/94

Adoptive immunotherapy has proven useful to treat human melanoma. The use of lymphokine activated killer cells and tumor infiltrating lymphocytes in conjunction with IL-2 have produced significant results in some terminal cancer patients. Recently, interferon alpha has been shown to have a synergistic effect with IL-2/TIL in animal TIL models....

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 01/15/91 - 07/15/91

DESCRIPTION: (Application's abstract) Adoptive immunotherapy has provided an additional method of treating cancer. The use of Lymphokine Activated Killer (LAK) cells and in conjunction with interleukin-2 have shown remarkable results in some terminal cancer patients. Recently IFN-a has been shown to have a synergistic effect in animal TIL mod...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 08/01/90 - 03/31/91

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 09/30/89 - 03/29/90

Conventional cancer treatments have been unable to eliminate malignant cells in a significant number of cancer patients despite continued with lymphokine activated killer (LAK) cells and rIL-2 has provided an additional therapy which has shown evidence of effect in situations where conventional therapies have failed. Tumor infiltrating lymphocyt...